ABSTRACT
Clinical data on the management of squamous-cell cervical carcinoma stage II-III FIGO are presented. At stage I, treatment included neoadjuvant polychemotherapy (NACT)--cisplatin 100 mg/m2, carboplatin 450 mg/m2 in conjunction with 5-FU 250 mg/m2 or paclitaxel 135 mg/m2. According to protocol, two identical courses of NACT were given, at 21-28 day interval, followed by extended extirpation of the uterus (Wertheim). Immediate results and complications caused by preoperative radiotherapy, important for postoperative one, were evaluated, concepts and strategies for postoperative intracavitary and distant radiotherapy worked out. To optimize radiotherapy, dosage was reduced by 10% or daily single target dose of intracavitary and distant irradiation split per 24 hrs, indications for preoperative radiotherapy variants were extended, and local dosage escalation in areas of lymphocyst or hematoma renounced. Overall survival was 85%, recurrence-free--77.5%.